Core Viewpoint - The merger between Inmagene Biopharmaceuticals and Ikena Oncology has been completed, resulting in the formation of ImageneBio, Inc., which will focus on advancing its lead asset, IMG-007, for the treatment of immunological and inflammatory diseases [1][2][3] Company Overview - ImageneBio, Inc. is a clinical-stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory diseases [6] - The company aims to create new medicines with differentiated profiles to effectively control and change the course of these diseases, improving patients' quality of life [6] Merger Details - The merger was finalized on July 25, 2025, and the combined company will trade on Nasdaq under the ticker symbol "IMA" starting July 28, 2025 [1][4] - A $75 million private placement was completed concurrently with the merger, involving both existing and new investors [2] Leadership - Kristin Yarema, Ph.D., has been appointed as the Chief Executive Officer of the combined company [2] Clinical Development - ImageneBio will continue the Phase 2b clinical trial of IMG-007, a non-depleting anti-OX40 monoclonal antibody, in patients with moderate-to-severe atopic dermatitis, with topline results expected in Q4 2026 [1][3] - IMG-007 has shown sustained clinical and pharmacodynamic activity in previous Phase 2a trials and is engineered to minimize safety risks [7] Stock Structure - Following a reverse stock split of 1-for-12 shares, legacy equity holders of Inmagene will own approximately 43.1% and legacy equity holders of Ikena will own approximately 35.3% of the combined company's outstanding common stock on a fully diluted basis [4]

Company Overview - Ikena Oncology, Inc. and Inmagene Biopharmaceuticals are merging to form a new entity named ImageneBio, Inc. The merger is expected to close by the end of July 2025, following shareholder approval on July 15, 2025, and includes a $75 million private placement [3]. Leadership Appointment - Kristin Yarema, Ph.D., has been appointed as the Chief Executive Officer of ImageneBio. She brings over two decades of leadership experience in human therapeutics, having previously served as CEO of Poseida Therapeutics and held senior roles at Atara Biotherapeutics and Amgen [2][3]. Product Development - The lead program of the combined company is IMG-007, a humanized, subcutaneously administered, non-depleting IgG1 monoclonal antibody targeting OX40. This therapeutic candidate has shown promise in treating autoimmune and inflammatory diseases, with recent Phase 2a trials demonstrating sustained clinical activity and good tolerability [4][6][7]. Clinical Trials - IMG-007 recently completed Phase 2a clinical trials for atopic dermatitis and alopecia areata, exhibiting sustained clinical and pharmacodynamic activity. The drug's formulation allows for a half-life of 34.7 days, supporting infrequent dosing [6][7]. Market Position - The combined company will trade on The Nasdaq Capital Market under the ticker symbol "IMA," indicating a strategic positioning in the biotechnology sector focused on immunological and inflammatory diseases [3].